Abstract: The present invention relates to a process for the preparation of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate as well as novel intermediates for use in said process. (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate is particularly useful as an HIV protease inhibitor.

Abstract: The present invention relates to an improved process for the preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine which is an intermediate for the preparation of the analgesic tapentadol.

Abstract: The present invention relates to a new high functionality MDI. In particular, this invention relates to polymeric allophanates based on diphenylmethane diisocyanate having an NCO group content of 12 to 30%, prepolymers thereof, and processes for the production of these compositions. The prepolymers are stable liquids having NCO group contents of about 10 to about 28%.

Abstract: The present invention relates to an improved method of synthesizing polyamines, the improvement comprising producing polyamines having an increased nitrogen content. It concerns the improved fuel additives thereby produced, and the resultant improved fuel composition which comprises an admixture of said fuel additive and a gasoline.

Abstract: The enantiomers of 2,2-dimethylcyclopropanecarboxylic acid are separated by salt formation with optically active 1-(3-methoxyphenyl)-ethylamine, fractional crystallization of the diastereomeric salts and subsequent decomposition of the salts with a strong acid.

Abstract: Intermediates of Formula ##STR1## where R is a methylthio, methylsulfoxy, methylsulfonyl or a nitro group; andX1 is hydrogen, 1-6 C alkyl, 1-6 C haloalkyl, 3-6 C cycloalkyl, phenyl or phenylalkyl(1-6C), where the phenyl ring may be substituted by one or two halogen, 1-3 C alkyl, 1-3 C alkoxy or nitro; orX1 together with X2 is an oxygen atom or an alkylene having from two to five Carbon atoms; orX1 together with X2 and R4 is a chain of formula ##STR2## where p is 3 or 4 and q is 1 or 2; and X2 is hydrogen, 1-6 C alkyl, 1-6 C haloalkyl, 3-6 C cycloalkyl or phenyl which may be substituted by one or two halogen, 1-3 C alkyl, 1-3 C alkoxy or nitro; orX2 together with R4 is ##STR3## where n is 1 or 2; m is 0 or 1; X is hydrogen, halogen, 1-3 C alkyl, 1-3 C alkoxy or nitro; andX3 is hydrogen or --CO--R4 where R4 is hydrogen, 1-6 alkyl, 1-6 C haloalkyl, 3-6 C cycloalkyl, phenylalkyl(1-6C) or phenyl where the phenyl ring may be substituted by one or two halogen, 1-3 alkyl, 1-3 alkoxy or nitro; andX4 is --OH, fluorine,

Abstract: The process of the invention for preparing a N-(2-substituted aminoethyl)amide of the formula: ##STR1## comprises contacting one or more compounds of the formula: ##STR2## with an amine of the formula: ##STR3## wherein A is nitrogen or a quaternary nitrogen of the formula: ##STR4## wherein B is ##STR5## when A is nitrogen and B is ##STR6## when A is IV; whereinX.sup..crclbar. is a counterion;b is zero or one; andR.sub.1 -R.sub.9 are as defined in the specification.In a preferred embodiment, the process is catalyzed by a Lewis acid or a protonic acid with a non-nucleophilic counterion.

Abstract: Novel phenethylamine derivatives represented by the general formula: ##STR1## wherein R is a lower alkyl group, C.sub.n H.sub.2n is a branched or straight alkylene group, A is a phenyl group unsubstituted or substituted with hydroxy, a lower alkoxy or a lower alkylene dioxy group, and n is an integer from 1 to 4, and pharmacologically acceptable acid addition salts thereof, and bronchdilator containing the same. These bronchdilator has an intense and durable bronchdilating effect and a weak heart stimulating action.